Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2004-08-25
2008-12-09
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S171000, C514S177000, C514S548000
Reexamination Certificate
active
07462646
ABSTRACT:
The present invention provides a method of reducing or inhibiting osteoclast development induced by the receptor for activation of nuclear factor kappa B ligand (RANKL), comprising the step of contacting said osteoclast, or a precursor of the osteoclast, with a pharmacologically effective dose of compounds such as diferuloylmethane, guggulsterone, 1′-Acetoxychavicol or analogues thereof.
REFERENCES:
patent: 4427649 (1984-01-01), Dingle et al.
patent: 5049388 (1991-09-01), Knight et al.
patent: 5401777 (1995-03-01), Ammon et al.
patent: 5494668 (1996-02-01), Patwardhan
patent: 5861415 (1999-01-01), Majeed et al.
patent: 5891924 (1999-04-01), Aggarwal
patent: 5925376 (1999-07-01), Heng
patent: 5958378 (1999-09-01), Waldrep et al.
patent: 6090407 (2000-07-01), Knight et al.
patent: 6106859 (2000-08-01), Densmore, Jr. et al.
patent: 6270747 (2001-08-01), Nadel et al.
patent: 6346233 (2002-02-01), Knight et al.
patent: 6375980 (2002-04-01), Densmore, Jr. et al.
patent: 6440393 (2002-08-01), Waldrep et al.
patent: 6440468 (2002-08-01), Quintanilla Almagro et al.
patent: 6462075 (2002-10-01), Bowen et al.
patent: 6492333 (2002-12-01), Mundy
patent: 6497908 (2002-12-01), Oshiro
patent: 6504048 (2003-01-01), Bachmann et al.
patent: 6566324 (2003-05-01), Nadel et al.
patent: 6576273 (2003-06-01), Madsen et al.
patent: 6664272 (2003-12-01), Snyder et al.
patent: 6673834 (2004-01-01), Kurz et al.
patent: 6673843 (2004-01-01), Arbiser
patent: 6998383 (2006-02-01), Aggarwal et al.
patent: 7030092 (2006-04-01), Levine
patent: 7105576 (2006-09-01), Aggarwal
patent: 7196105 (2007-03-01), Aggarwal
patent: 7371766 (2008-05-01), Snyder et al.
patent: 2001/0025034 (2001-09-01), Arbiser
patent: 2001/0036919 (2001-11-01), Nadel et al.
patent: 2001/0051184 (2001-12-01), Heng
patent: 2002/0006966 (2002-01-01), Arbiser
patent: 2002/0019382 (2002-02-01), Snyder et al.
patent: 2002/0035090 (2002-03-01), Zeldis et al.
patent: 2002/0058009 (2002-05-01), Bartus et al.
patent: 2002/0058695 (2002-05-01), Majeed et al.
patent: 2002/0192274 (2002-12-01), Ponnappa
patent: 2003/0021752 (2003-01-01), Whittle et al.
patent: 2003/0027830 (2003-02-01), Bowen et al.
patent: 2003/0096027 (2003-05-01), Babish et al.
patent: 2003/0118672 (2003-06-01), McPeak et al.
patent: 2003/0149113 (2003-08-01), Caplan et al.
patent: 2003/0190381 (2003-10-01), Bland et al.
patent: 2004/0058021 (2004-03-01), Aggarwal
patent: 2004/0167072 (2004-08-01), Aggarwal et al.
patent: 2004/0176384 (2004-09-01), Snyder et al.
patent: 2005/0049299 (2005-03-01), Aggarwal
patent: 2005/0069551 (2005-03-01), Shoji et al.
patent: 2005/0148599 (2005-07-01), Bowen et al.
patent: 2005/0181036 (2005-08-01), Aggarwal et al.
patent: 2005/0201976 (2005-09-01), Aggarwal
patent: 2006/0019907 (2006-01-01), Aggarwal et al.
patent: 2006/0210656 (2006-09-01), Aggarwal
patent: 2006/0233899 (2006-10-01), Aggarwal
patent: 2007/0270464 (2007-11-01), Liotta et al.
patent: 0317281 (1989-05-01), None
patent: 0923941 (1999-06-01), None
patent: WO 00/70949 (2000-11-01), None
patent: WO 01/40188 (2001-06-01), None
patent: WO 03/006033 (2003-01-01), None
patent: WO 03/090681 (2003-11-01), None
patent: WO 2004/091578 (2004-10-01), None
Bharti et al., “Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kB and Ikbalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis,”Blood, 101:1053-1062, 2003.
Bucay et al., “osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,”Genes Dev., 12:1260-1268, 1998.
Hsu et al., “Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,”Proc. Natl. Acad. Sci. USA, 96:3540-3545, 1999.
Kong et al., “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,”Nature, 397:315-323, 1999.
Kumar et al., “Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation,”Biochem. Pharmacol., 55:775-783 1998.
Lacey et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,”Cell, 93:165-176, 1998.
Li et al., “RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism,”Proc Natl. Acad Sci USA, 97:1566-1571, 2000.
Lomaga et al., “TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling,”Genes Dev., 13:1015-1024, 1999.
Singh and Aggarwal, “Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane),”J. Biol. Chem., 270:24995-25000, 1995.
“Analogue,” Merriam-Webster's Medical Desk Dictionary, Merriam-Webster, Inc., Springfield, MA, p. 34, 1996.
Ishida et al., “Antitumor agents. Part 214: synthesis and evaluation of curcumin analogues as cytotoxic agents,”Bioorg. Med. Chem., 10:3481-3487, 2002.
Khopde et al., “Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue,”Biophys. Chem., 80:85-91, 1999.
Kumar et al., “4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management,”Neoplasia, 5:255-266, 2003.
Lin et al., “Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumorigenesis in Sencar mice,”Cancer Lett., 168:125-132, 2001.
Vajragupta et al., “Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis,”Free Radic. Res., 38:303-314, 2004.
Wu et al., “The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor,”Mol. Endocrinol., 16:1590-1597, 2002.
“Turmeric Tales,” Food Product Design: Spice Rack, Mar. 2001 www.foodproductDesign.com/archive/2001/0301sr.html.
Aggarwal et al., “Anticancer potential of curcurmin: preclinical and clinical studies,” Anticancer Research, 23:363-398, 2003.
Alexanian et al., “High-dose Glucocorticoid Treatment of Resistant Myeloma,”Ann. Int. Med., 105:8-11, 1986.
Arbuck et al., “Cancer Therapy Evalutation Program, national Cnacer Institute, Bethesda, Maryland,”Hematology/oncology clinics of North America, 8(1): 121-140, Medline Abstract AN94201161, 1994,
Asai and Miyazawa, “Dietary Curcuminoids prevent high-fat-diet-induced lipid accumulation in rat liver and epididymal adipose tissue,”J. Nutr., 131:2932-2935, 2001.
Asai and Miyazawa, “Occurrence of orally administered Curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma,”Life Sci., 67:2785-2793, 2000.
Berenson et al., “The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma,”Semin. Oncol., 28(6):626-633, 2001.
Bredel, “Anticancer drug resistance in primary human brain tumors,”Brain Red. Brain Res. Rev., 35:161-204, 2001.
Brennan and O'Neil, “Inhibition of nuclear factor KappaB by direct modification in whole cells-mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers,”Biochem. Pharmacol., 55:965-973, 1998.
Chaturvedi et al., “Assay for redox-sensitive transctiption facotr,”Methods Enzymol., 319:585-602, 2000.
Chaturvedi et al., “Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response,”J. Biol. Chem., 269:14575, 1994.
Cheng et al., “Phase I chemoprevention clinical trial of curcumin,”Proc. Am
Fulbright & Jaworski LLP
Henley, III Raymond J
Research Development Foundation
LandOfFree
Osteoclastogenesis inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Osteoclastogenesis inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteoclastogenesis inhibitors and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4027999